Bookser, Brett C.; Kasibhatla, Srinivas Rao; Appleman, James R.; Erion, Mark D. published the artcile< AMP Deaminase Inhibitors. 2. Initial Discovery of a Non-Nucleotide Transition-State Inhibitor Series>, SDS of cas: 14062-30-7, the main research area is coformycin aglycon analog preparation AMPDA inhibitor; adenylate adenosine deaminase inhibitor coformycin analog.
A series of N3-substituted coformycin aglycon analogs are described that inhibit AMP deaminase (AMPDA) or adenosine deaminase (ADA). The key steps involved in the preparation of these compounds are treating the sodium salt of 6,7-dihydroimidazo[4,5-d][1,3]diazepin-8(3H)-one with an alkyl bromide or an alkyl mesylate to generate the N3-alkylated compound, and (2) reducing the N3-alkylated compound with NaBH4. Selective inhibition of AMPDA was realized when the N3-substituent contained a carboxylic acid moiety. For example, the compound which has a hexanoic acid side chain inhibited AMPDA with a Ki = 4.2 μM and ADA with a Ki = 280 μM. Substitution of large lipophilic groups α to the carboxylate provided a moderate potency increase with maintained selectivity as exemplified by the α-benzyl analog (AMPDA Ki = 0.41 μM and ADA Ki > 1000 μM). These compounds, as well as others described in this series of papers, are the first compounds suitable for testing whether selective inhibition of AMPDA can protect tissue from ischemic damage by increasing local adenosine concentrations at the site of injury and/or by minimizing adenylate loss.
Journal of Medicinal Chemistry published new progress about Structure-activity relationship, enzyme-inhibiting. 14062-30-7 belongs to class bromides-buliding-blocks, and the molecular formula is C10H11BrO2, SDS of cas: 14062-30-7.
Referemce:
Bromide – Wikipedia,
bromide – Wiktionary